Why Is CareDx Stock Skyrocketing Thursday?

Benzinga07-17

Following the announcement, the stock jumped nearly 29%. The precision medicine diagnostics company said the final policy provides continued Medicare coverage for its transplant surveillance portfolio...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652755054?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/16/CareDx-Photo-by-Pavel-Kapysh-via-Shutter.jpg","is_english":true,"pubTime":"2026-07-17 02:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652755054","market":"hk","top_or_hot":-1,"title":"Why Is CareDx Stock Skyrocketing Thursday?","media":"Benzinga","content":"<div>\n<p>Following the announcement, the stock jumped nearly 29%.\nThe precision medicine diagnostics company said the final policy provides continued Medicare coverage for its transplant surveillance portfolio...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/07/60508392/why-is-caredx-stock-skyrocketing-thursday\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is CareDx Stock Skyrocketing Thursday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is CareDx Stock Skyrocketing Thursday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-17 02:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/07/60508392/why-is-caredx-stock-skyrocketing-thursday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following the announcement, the stock jumped nearly 29%.\nThe precision medicine diagnostics company said the final policy provides continued Medicare coverage for its transplant surveillance portfolio...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/07/60508392/why-is-caredx-stock-skyrocketing-thursday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/07/60508392/why-is-caredx-stock-skyrocketing-thursday","article_id":"2652755054","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/16/CareDx-Photo-by-Pavel-Kapysh-via-Shutter.jpg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/07/60508392/why-is-caredx-stock-skyrocketing-thursday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652755054","pubTimestamp":1784225280,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"CareDx ($CDNA) shares surge 28% as Medicare finalizes continued coverage for its kidney, heart, and lung transplant tests.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CDNA":"CareDx"},"translate_title":"为什么 CareDx 股价周四飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1.5},"content_text":"Following the announcement, the stock jumped nearly 29%.\nThe precision medicine diagnostics company said the final policy provides continued Medicare coverage for its transplant surveillance portfolio and maintains coverage for clinically indicated, for-cause testing across all three organ types.\nUnder the finalized policy, Medicare will cover surveillance testing with AlloSure Kidney for up to six tests during the first year following a transplant.\nCoverage also includes up to four surveillance tests annually during the second and third years after transplantation.\nCareDx noted that patients using AlloSure Kidney currently receive an average of approximately three to four tests during the first year after a transplant.\nCoverage for for-cause testing remains unchanged and is available when clinically indicated.\nFor heart transplant recipients, Medicare will continue covering both AlloMap and AlloSure Heart. The policy also allows the two tests to be used together when medically appropriate.\nThe finalized coverage includes up to 12 surveillance tests during the first post-transplant year and up to four tests annually in the second and third years. Coverage for for-cause testing remains unchanged when clinically necessary.\nThe final Medicare policy also maintains coverage for AlloSure Lung, including up to 12 surveillance tests during the first year after transplantation and four annual tests during years two and three.\nAccording to CareDx, these coverage criteria align with the need for frequent monitoring during the early post-transplant period for lung transplant patients.\nCareDx described itself as a precision medicine diagnostics company focused on advancing care in transplant, specialty oncology, and cell therapy. \nThe company said the finalized Medicare policy affirms coverage across its transplant surveillance offerings for kidney, heart, and lung recipients.\nPhoto by Pavel Kapysh via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652755054","isCrawlerRequest":true}